Risk Assessment and Management of Peripheral Blood Blasts Post-Stem Cell Transplant in AML

Definition and Diagnosis of Relapse

• The National Comprehensive Cancer Network recommends that complete remission requires 0% blasts in peripheral blood 1, 2
• Morphologic relapse is defined as ≥5% blasts in bone marrow not attributable to regeneration, or reappearance of leukemic blasts in peripheral blood, or cytogenetic/molecular relapse 1, 4, 6
• The presence of 3% blasts in peripheral blood does not automatically indicate relapse in the post-transplant setting, and clinical context is paramount 1, 2

Diagnostic Algorithm

• The National Comprehensive Cancer Network suggests performing bone marrow aspirate and biopsy immediately with morphologic assessment, repeat flow cytometry, cytogenetics, and chimerism studies 2, 3
• Morphologic assessment should include a 500-cell differential count, as a 100-cell count has unacceptably wide confidence intervals 5

Relapse Risk Stratification

• The National Comprehensive Cancer Network identifies high-risk features for relapse, including poor-risk cytogenetics at diagnosis, therapy-related AML, prior myelodysplastic syndrome, required >1 induction cycle to achieve initial CR, and time from transplant 2, 4, 7
• Favorable indicators include negative flow cytometry and low percentage of blasts 1, 3, 4

Monitoring Strategy

• The National Comprehensive Cancer Network recommends monitoring with CBC with differential 2-3 times weekly until counts stabilize, and repeat bone marrow if peripheral blood abnormalities persist or worsen 2
• Consider MRD monitoring if molecular markers were present at diagnosis 3